Immunic (IMUX) Income from Continuing Operations (2013 - 2026)
Immunic (IMUX) reported Income from Continuing Operations of 35805853.0 for Q1 2026, down 34.31% on a YoY basis from 54509304.76 in Q1 2025, and down 53.43% sequentially from 23337000.0 in Q4 2025.
Immunic (IMUX) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Immunic (IMUX) has 14 years of Income from Continuing Operations data on file, last reported at 35805853.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 34.31% year-over-year to 35805853.0; the trailing twelve-month figure through Mar 2026 stood at 112699815.0 (down 11.08% YoY), and the FY2025 full-year result was 222061000.0, down 4.87% from the prior year.
- Income from Continuing Operations fell to 35805853.0 in Q1 2026, from 23337000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 19888400.0 in Q3 2022 to a low of 129682000.0 in Q4 2022.
- A 5-year average of 31171853.53 and a median of 25240000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations tumbled 61.05% in 2022 and jumped 81.61% in 2023, its largest moves.
- Tracing IMUX's Income from Continuing Operations over 5 years: stood at 129682000.0 in 2022, then jumped by 81.61% to 23854000.0 in 2023, then slipped by 5.81% to 25240000.0 in 2024, then gained by 7.54% to 23337000.0 in 2025, then plunged by 53.43% to 35805853.0 in 2026.
- Business Quant data shows IMUX's Income from Continuing Operations at 35805853.0 in Q1 2026, 23337000.0 in Q4 2025, and 26632962.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Immunic | 11.03 Mn | 11.03 Mn | - | -35.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.81 Mn |
| Dec 31, 2025 | -23.34 Mn |
| Sep 30, 2025 | -26.63 Mn |
| Jun 30, 2025 | -26.92 Mn |
| Mar 31, 2025 | -26.66 Mn |
| Dec 31, 2024 | -25.24 Mn |
| Sep 30, 2024 | -27.74 Mn |
| Jun 30, 2024 | -21.82 Mn |
| Mar 31, 2024 | -23.16 Mn |
| Dec 31, 2023 | -23.85 Mn |
| Sep 30, 2023 | -22.92 Mn |
| Jun 30, 2023 | -26.22 Mn |
| Mar 31, 2023 | -26.61 Mn |
| Dec 31, 2022 | -129.68 Mn |
| Sep 30, 2022 | -19.89 Mn |
| Jun 30, 2022 | -20.53 Mn |
| Mar 31, 2022 | -22.89 Mn |
| Dec 31, 2021 | -80.52 Mn |
| Sep 30, 2021 | -18.45 Mn |
| Jun 30, 2021 | -19.57 Mn |